Craft
Moderna

Moderna

Program Expenses (Cancer Vaccines)

$3 M

Q1, 2022

Revenue

$18.5 B

FY, 2021

Market Capitalization

$77.2 B

2023-01-19

Moderna Summary

Company summary

Overview
Moderna is a biotechnology company that develops therapeutics and vaccines. It provides medicine for treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. The company caters to the healthcare sector.
Type
Public
Status
Active
Founded
2010
HQ
Cambridge, MA, US | view all locations
Website
http://www.modernatx.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Stephen Hoge
  • Noubar Afeyan

    Noubar Afeyan, Co-founder and Chairman

  • Stephane Bancel

    Stephane Bancel, Chief Executive Officer, Board Member

  • Juan Andres

    Juan Andres, Chief Technical Operations and Quality Officer

Operating MetricsView all

Program Expenses (Systemic Intracellular Therapeutics)

$4M
20.0%

Q1, 2022

Program Expenses (Cancer Vaccines)

$3M
82.4%

Q1, 2022

Patent Applications

430
28.3%

FY, 2021

LocationsView all

2 locations detected

  • Cambridge, MA HQ

    United States

    200 Technology Square

  • Norwood, MA

    United States

    100 Upland Rd

Moderna Financials

Summary financials

Revenue (Q3, 2022)
$3.4B
Gross profit (Q3, 2022)
$2.3B
Net income (Q3, 2022)
$1.0B
Cash (Q3, 2022)
$3.0B
EBIT (Q3, 2022)
$1.2B
Enterprise value
$75.3B

Footer menu